Simultaneous determination of levodopa and 3-O-methyldopa in patients with parkinson’s disease by high-performance liquid chromatography with electrochemical detection

Adamiak-Giera, Urszula; Gawrońska-Szklarz, B

doi:10.1080/10826076.2018.1556162

Cited by 6 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma was transferred into polypropylene tubes and immediately frozen at −30 °C until analysis within 14 days. Levodopa and 3-OMD plasma concentrations were determined by specific reversed-phase high-performance liquid chromatographic method with electrochemical detection, according to the technique previously reported by Saxer [ 25 ] with our own modification [ 26 ]. Chromatographic separation was carried out on analytical column C18 ThermoHypersil Gold 3 mm (3.0 × 100 mm) (Thermo).…”

Section: Methodsmentioning

confidence: 99%

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications

Adamiak-Giera,

Jawień,

Pierzchlińska

et al. 2021

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive, neurodegenerative disorder primarily affecting dopaminergic neuronal systems, with impaired motor function as a consequence. The most effective treatment for PD remains the administration of oral levodopa (LD). Long-term LD treatment is frequently associated with motor fluctuations and dyskinesias, which exert a serious impact on a patient’s quality of life. The aim of our study was to determine the pharmacokinetics of LD: used as monotherapy or in combination with ropinirole, in patients with advanced PD. Furthermore, an effect of ropinirole on the pharmacokinetics of 3-OMD (a major LD metabolite) was assessed. We also investigated the correlation between the pharmacokinetic parameters of LD and 3-OMD and the occurrence of motor complications. Twenty-seven patients with idiopathic PD participated in the study. Thirteen patients received both LD and ropinirole, and fourteen administered LD monotherapy. Among 27 patients, twelve experienced fluctuations and/or dyskinesias, whereas fifteen were free of motor complications. Inter- and intra-individual variation in the LD and 3-OMD concentrations were observed. There were no significant differences in the LD and 3-OMD concentrations between the patients treated with a combined therapy of LD and ropinirole, and LD monotherapy. There were no significant differences in the LD concentrations in patients with and without motor complications; however, plasma 3-OMD levels were significantly higher in patients with motor complications. A linear one-compartment pharmacokinetic model with the first-order absorption was adopted for LD and 3-OMD. Only mean exit (residence) time for 3-OMD was significantly shorter in patients treated with ropinirole. Lag time, V/F, CL/F and tmax of LD had significantly lower values in patients with motor complications. On the other hand, AUC were significantly higher in these patients, both for LD and 3-OMD. 3-OMD Cmax was significantly higher in patients with motor complications as well. Our results showed that ropinirole does not influence LD or 3-OMD concentrations. Higher 3-OMD levels play a role in inducing motor complications during long-term levodopa therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications

Adamiak-Giera,

Jawień,

Pierzchlińska

et al. 2021

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some analytical methods have been developed for individual and simultaneous determination of L-dopa and BEZ in pharmaceutical and biological samples using mainly spectrophotometric [ 4 , 5 , 6 ] and chromatographic [ 7 , 8 , 9 ] techniques. However, in general, these procedures involve some extraction, the use of toxic solvents, and are highly time-consuming.…”

Section: Introductionmentioning

confidence: 99%

Electrochemical Sensor Based on Multi-Walled Carbon Nanotubes and N-Doped TiO2 Nanoparticles for Voltametric Simultaneous Determination of Benserazide and Levodopa

et al. 2022

View full text Add to dashboard Cite

An electrochemical sensor for simultaneous determination of Benserazide (BEZ) and levodopa (L-dopa) was successfully developed using a glassy carbon electrode (GCE) modified with multi-walled carbon nanotube and nitrogen-doped titanium dioxide nanoparticles (GCE/MWCNT/N-TiO2). Cyclic voltammetry and square wave voltammetry were employed to investigate the electrochemical behavior of different working electrodes and analytes. In comparison with unmodified GCE, the modified electrode exhibited better electrocatalytic activity towards BEZ and L-dopa and was efficient in providing a satisfactory separation for oxidation peaks, with a potential difference of 140 mV clearly allows the simultaneous determination of these compounds. Under the optimized conditions, linear ranges of 2.0–20.0 and 2.0–70.0 μmol L−1 were obtained for BEZ and L-dopa, respectively, with a limit of detection of 1.6 µmol L−1 for BEZ and 2.0 µmol L−1 for L-dopa. The method was applied in simultaneous determination of the analytes in pharmaceutical samples, and the accuracy was attested by comparison with HPLC-DAD as the reference method, with a relative error lower than 4.0%.

show abstract

“…Techniques such as chromatography (Adamiak-Giera and Gawronska-Szklarz, 2018;Loutelier-Bourhis et al, 2004;Martins et al, 2013), spectrophotometry (Uslu and Özkan, 2002), chemiluminescence (He et al, 2006) and voltammetry (Miraki et al, 2019;Ensafi et al, 2010) have also been used in the analysis of benserazide and levodopa binary drug mixture. The common feature of these substances is that they have a monoamine neurotransmitter substance structure that does not contain chromophore groups.…”

Section: Introductionmentioning

confidence: 99%

Voltammetric Detection of Levodopa and Benserazide at Polypyrrole and Single Walled Carbon Nanotube Based Electrode

Savan

Erdoğdu

2021

International Journal of Pure and Applied Sciences

View full text Add to dashboard Cite

In this study, it was aimed to use pyrrole monomer and single-walled carbon nanotube (SWCNT) in the production of modified electrodes, and to examine the electrochemical properties of these electrodes. Bulk electrolysis technique was used for growing polypyrrole. The applicability of the polypyrrole and SWCNT-based electrodes was tested by electrochemically detecting active substances such as levodopa (LD) and benserazide (BS) used in the treatment of Parkinson's disease. During the design and analysis phase of the modified electrode, many electroanalytical optimization and validation parameters were examined. The developed modified electrode gave linear responses with DPV technique in concentration ranges of 10 -50 µM for LD and 10 -50 µM for BS. In addition, limits of detection in these wide linear ranges were obtained as very low. Limits of detection were calculated as 2.4 µM and 1.2 µM for LD and BS, respectively. In addition, the applicability of the designed electrode and method was tested in urine and drug samples. The selectivity of this electrode was carried out in placebo solutions containing the interfering species. It is advantageous that the drug active ingredients are easily, selectively and quickly determined at this modified electrode in the presence of components that affect the analysis. Eventually, very satisfactory results in terms of analytical performance and applicability have been achieved with the designed electrode.

show abstract

Simultaneous determination of levodopa and 3-O-methyldopa in patients with parkinson’s disease by high-performance liquid chromatography with electrochemical detection

Cited by 6 publications

References 10 publications

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications

Electrochemical Sensor Based on Multi-Walled Carbon Nanotubes and N-Doped TiO2 Nanoparticles for Voltametric Simultaneous Determination of Benserazide and Levodopa

Voltammetric Detection of Levodopa and Benserazide at Polypyrrole and Single Walled Carbon Nanotube Based Electrode

Contact Info

Product

Resources

About